 Quinuclidines
"Quinuclidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011812
|
| MeSH Number(s) |
D03.605.687
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinuclidines".
Below are MeSH descriptors whose meaning is more specific than "Quinuclidines".
This graph shows the total number of publications written about "Quinuclidines" by people in this website by year, and whether "Quinuclidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinuclidines" by people in Profiles.
-
Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
-
Umana IC, Daniele CA, Miller BA, Abburi C, Gallagher K, Brown MA, Mason P, McGehee DS. Nicotinic modulation of descending pain control circuitry. Pain. 2017 Oct; 158(10):1938-1950.
-
Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
-
Navari RM. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61.
-
Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
-
Navari R. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
-
Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.
-
Kaushal J, Gupta MC, Kaushal V, Bhutani G, Dhankar R, Atri R, Verma S. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J. 2010 Nov; 51(11):871-5.
-
Avritscher EB, Shih YC, Sun CC, Gralla RJ, Grunberg SM, Xu Y, Elting LS. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.
-
Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010 Jul; 6(7):1073-84.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|